The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Open accessAbstract
BACKGROUND: The effect of screening with prostate-specific-antigen (PSA) testing and digital rectal examination on the rate of death from prostate cancer is unknown. This is the first report from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial on prostate-cancer mortality. METHODS: From 1993 through 2001, we randomly assigned 76,693 men at 10 U.S. study centers to receive either annual screening (38,343 subjects) or usual care as the control (38,350 subjects). Men in the screening group were offered annual PSA testing for 6 years and digital rectal examination for 4 years. The subjects and health care providers received the results and decided on the type of follow-up evaluation. Usual care sometimes included screening, as some organizations have recommended. The numbers of all cancers and deaths and causes of death were ascertained. RESULTS: In the screening group, rates of compliance were 85% for PSA testing and 86% for digital rectal examination. Rates of screening in the control group increased from 40% in the first year to 52% in the sixth year for PSA testing and ranged from 41 to 46% for digital rectal examination. After 7 years of follow-up, the incidence of prostate cancer per 10,000 person-years was 116 (2820 cancers) in the screening group and 95 (2322 cancers) in the control group (rate ratio, 1.22; 95% confidence interval [CI], 1.16 to 1.29). The incidence of death per 10,000 person-years was 2.0 (50 deaths) in the screening group and 1.7 (44 deaths) in the control group (rate ratio, 1.13; 95% CI, 0.75 to 1.70). The data at 10 years were 67% complete and consistent with these overall findings. CONCLUSIONS: After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups. (ClinicalTrials.gov number, NCT00002540.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J. R., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Bratell, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011967 · Cited by 1,900
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Häggman, M., Andersson, S.-O., Bratell, S., Spångberg, A., Busch, C., Nordling, S., Garmo, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043739 · Cited by 1,111
Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., & de Koning, H. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.868 · Cited by 1,071
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., David Crawford, E., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., et al. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00098-2 · Cited by 1,037
Self-citationPotosky, A. L., Davis, W. W., Hoffman, R. M., Stanford, J. L., Stephenson, R. A., Penson, D. F., & Harlan, L. C. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh259 · Cited by 680
The Role of Increasing Detection in the Rising Incidence of Prostate Cancer
Potosky, A. L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520310046028 · Cited by 674
Research works printed but not linked: 5
- 10.1001/jama.273.7.548 · doi:10.1001/jama.273.7.548
- 2000, Oncology (Williston Park), 14, 267
- 10.1111/j.1464-410X.2008.08214.x · doi:10.1111/j.1464-410x.2008.08214.x
- 10.1097/01.ju.0000152697.25708.71 · doi:10.1097/01.ju.0000152697.25708.71
- 10.1016/S0197-2456(00)00095-7 · doi:10.1016/s0197-2456(00)00095-7
Cited by
Items 101–115 of 115
Hayes, J. H., Ollendorf, D. A., Pearson, S. D., Barry, M. J., Kantoff, P. W., Stewart, S. T., Bhatnagar, V., Sweeney, C. J., Stahl, J. E., & McMahon, P. M. (2010) · JAMA · doi:10.1001/jama.2010.1720 · Cited by 257
Pinsky, P. F., Prorok, P. C., Yu, K., Kramer, B. S., Black, A., Gohagan, J. K., Crawford, E. D., Grubb, R. L., & Andriole, G. L. (2017) · Cancer · doi:10.1002/cncr.30474 · Cited by 256
Self-citationBancroft, E. K., Page, E. C., Castro, E., Lilja, H., Vickers, A., Sjoberg, D., Assel, M., Foster, C. S., Mitchell, G., Drew, K., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.01.003 · Cited by 254
Self-citationReconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Tsodikov, A., Gulati, R., Heijnsdijk, E. A. M., Pinsky, P. F., Moss, S. M., Qiu, S., de Carvalho, T. M., Hugosson, J., Berg, C. D., Auvinen, A., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2586 · Cited by 251
Self-citationA systematic review of artificial intelligence techniques in cancer prediction and diagnosis
Kumar, Y., Gupta, S., Singla, R., & Hu, Y.-C. (2022) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-021-09648-w · Cited by 223
Sussman, J. B., & Hayward, R. A. (2010) · BMJ · doi:10.1136/bmj.c2073 · Cited by 176
on behalf of the Transatlantic Prostate Group, Cuzick, J., Stone, S., Fisher, G., Yang, Z. H., North, B. V., Berney, D. M., Beltran, L., Greenberg, D., Møller, H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.223 · Cited by 155
Petrelli, N. J., Winer, E. P., Brahmer, J., Dubey, S., Smith, S., Thomas, C., Vahdat, L. T., Obel, J., Vogelzang, N., Markman, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6171 · Cited by 121
Self-citationPrevalence of major risk factors and use of screening tests for cancer in the United States
Fedewa, S. A., Sauer, A. G., Siegel, R. L., & Jemal, A. (2015) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0134 · Cited by 77
Owens, O. L., Felder, T., Tavakoli, A. S., Revels, A. A., Friedman, D. B., Hughes-Halbert, C., & Hébert, J. R. (2019) · American Journal of Health Promotion · doi:10.1177/0890117118786866 · Cited by 65
Xu, M., Evans, L., Bizzaro, C. L., Quaglia, F., Verrillo, C. E., Li, L., Stieglmaier, J., Schiewer, M. J., Languino, L. R., & Kelly, W. K. (2022) · Cancers · doi:10.3390/cancers14164034 · Cited by 61
Testosterone administration in older men
Matsumoto, A. M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.02.011 · Cited by 32
Jeihooni, A. K., Kashfi, S. M., Hatami, M., Avand, A., & Bazrafshan, M.-R. (2019) · Journal of Cancer Education · doi:10.1007/s13187-017-1282-8 · Cited by 28
Matsumoto, A. M., & Bremner, W. J. (2011) · Williams Textbook of Endocrinology · doi:10.1016/b978-1-4377-0324-5.00019-5 · Cited by 18
Huang, M., Chen, L., Ma, X., & Xu, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03542-8 · Cited by 9
“Prostate cancer (PCa) is one of the most prevalent malignancies affecting men globally, marked by its heterogeneous nature and variable clinical outcomes [1, 2].”
Background
Metadata
- Authors
- Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., Weissfeld, J. L., Yokochi, L. A., O'Brien, B., Clapp, J. D., Rathmell, J. M., Riley, T. L., Hayes, R. B., Kramer, B. S., Izmirlian, G., Miller, A. B., Pinsky, P. F., Prorok, P. C., Gohagan, J. K., & Berg, C. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-03-26
- Volume
- 360
- Issue
- 13
- Pages
- 1310-1319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2132528779
- Cited by
- 2,906
- References
- 27
- FWCI
- 314.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.